Publication:
Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: Quantum chemical calculations based on the ONIOM method

dc.contributor.authorSaen-Oon S.
dc.contributor.authorKuno H.
dc.contributor.authorHannongbua S.
dc.date.accessioned2021-04-05T04:32:29Z
dc.date.available2021-04-05T04:32:29Z
dc.date.issued2005
dc.date.issuedBE2548
dc.description.abstractTwo-layered and three-layered ONIOM calculations were performed to compare the binding energies of 8-Cl TIBO inhibitor when bound into the human immunodeficiency virus reverse transcriptase binding pocket and a Y181C variant. Both consisted of 20 residues within a radius of 15 Å. A combination of different methods [HP2/6-31G(d), B3LYP/6-31G(d,p), and PM3] were performed to take advantage of ONIOM's layering strategy analysis. The obtained results clearly indicate that the Y181C mutation reduces the binding affinity and stability of the inhibitor by approximately 8-9 kcal/mol as obtained from different combined MO:MO methods. Analyses regarding the energetic components of the interaction and deformation energies for 8-Cl TIBO inhibitor upon binding were also examined extensively. Additional calculations involving the interaction energies between 8-Cl TIBO with individual residues surrounding the binding pocket were performed at MP2/6-31G(d,p) and B3LYP/6-31G(d,p) levels of theory to gain more insight into the energetic differences of wild-type and Y181C mutant type at the atomistic level. © 2005 Wiley-Liss, Inc.
dc.format.mimetypeapplication/pdf
dc.identifier.citationProteins: Structure, Function and Genetics. Vol 61, No.4 (2005), p.859-869
dc.identifier.doi10.1002/prot.20690
dc.identifier.issn8873585
dc.identifier.other2-s2.0-28644442414
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6042
dc.rights.holderScopus
dc.subject.other4,5,6,7 tetrahydroimidazo 8 chloro 5 methyl (3 methyl 2 butenyl)imidazo
dc.subject.otherRNA directed DNA polymerase
dc.subject.otherRNA directed DNA polymerase inhibitor
dc.subject.otherUnclassified drug
dc.subject.otherAnalytic method
dc.subject.otherArticle
dc.subject.otherBinding affinity
dc.subject.otherCalculation
dc.subject.otherComparative study
dc.subject.otherComplex formation
dc.subject.otherDrug binding site
dc.subject.otherDrug protein binding
dc.subject.otherEnergy
dc.subject.otherHuman immunodeficiency virus 1
dc.subject.otherMolecular stability
dc.subject.otherMutation
dc.subject.otherNonhuman
dc.subject.otherPriority journal
dc.subject.otherQuantum chemistry
dc.subject.otherWild type
dc.subject.otherAmino Acid Substitution
dc.subject.otherDimerization
dc.subject.otherHIV-1
dc.subject.otherKinetics
dc.subject.otherModels, Molecular
dc.subject.otherPolymorphism, Single Nucleotide
dc.subject.otherProtein Structure, Secondary
dc.subject.otherProtein Subunits
dc.subject.otherQuantum Theory
dc.subject.otherRecombinant Proteins
dc.subject.otherReverse Transcriptase Inhibitors
dc.subject.otherRNA-Directed DNA Polymerase
dc.subject.otherThermodynamics
dc.subject.otherHuman immunodeficiency virus
dc.subject.otherHuman immunodeficiency virus 1
dc.titleBinding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: Quantum chemical calculations based on the ONIOM method
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-28644442414&doi=10.1002%2fprot.20690&partnerID=40&md5=bdfa20e816813bf3ae48971687134dd4

Files